

## Appendix: Patient Group Conflict of Interest Declaration

To maintain the objectivity and credibility of the CADTH CDR and pCODR programs, all participants in the drug review processes must disclose any real, potential, or perceived conflicts of interest. This Patient Group Conflict of Interest Declaration is required for participation. Declarations made do not negate or preclude the use of the patient group input. CADTH may contact your group with further questions, as needed.

1. Did you receive help from outside your patient group to complete this submission? If yes, please detail the help and who provided it.

**Childhood Cancer Canada provided Ac2orn with the use of their Survey Monkey account to administer the English survey. They only provided access to Survey Monkey and Ac2orn did all of the English survey set-up and analysis.**

2. Did you receive help from outside your patient group to collect or analyze data used in this submission? If yes, please detail the help and who provided it.

No

3. List any companies or organizations that have provided your group with financial payment over the past two years AND who may have direct or indirect interest in the drug under review.

Company

I hereby certify that I have the authority to disclose all relevant information with respect to any matter involving this patient group with a company, organization, or entity that may place this patient group in a real, potential, or perceived conflict of interest situation.

Name: Antonia Palmer  
Position: Co-Founder  
Patient Group: Ac2orn  
Date: October 11, 2018

Name: Durhane Wong-Rieger  
Position: President and CEO  
Patient Group: Canadian Organization for Rare Disorders (CORD)  
Date: October 11, 2018

Name: Sarai Porretta  
Position: Administrative Coordinator  
Patient Group: OPACC  
Date: October 11, 2018